Document Detail

Administration of glucocorticoids in boys with duchenne muscular dystrophy.
MedLine Citation:
PMID:  24305455     Owner:  NLM     Status:  In-Data-Review    
Duchenne muscular dystrophy (DMD) is the most common neuromuscular disease affecting boys. Advances in their care can delay the progression of DMD-related disability and prolong survival. The administration of glucocorticoids is among these advances. Glucocorticoid therapy, however, is associated with a myriad of potential adverse effects, and treating physicians as well as patients and their family members must understand the benefit/risk ratio of glucocorticoid therapy. Although current best evidence supports the use of glucocorticoids in patients with DMD, many are not offered the option. Considerable variability in practice also exists regarding when and how these drugs should be administered.
Amparo Gutierrez; John D England
Related Documents :
12425405 - Oxidative stress in critically ill patients.
17006385 - Use of fenoldopam to increase urine output in a patient with renal insufficiency second...
2688775 - Day-hospital and community treatment for acute psychiatric illness. a critical appraisal.
15461885 - Advances in sepsis treatment.
16641765 - Questionnaire survey of spine surgeons on the use of methylprednisolone for acute spina...
16612765 - Acute eosinophilic pneumonia.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Continuum (Minneapolis, Minn.)     Volume:  19     ISSN:  1538-6899     ISO Abbreviation:  Continuum (Minneap Minn)     Publication Date:  2013 Dec 
Date Detail:
Created Date:  2013-12-05     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9509333     Medline TA:  Continuum (Minneap Minn)     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1703-8     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The new frontier of genetically targeted therapies for muscle disease.
Next Document:  Increased soluble IL-2 receptor levels in serum from a patient with painless thyroiditis.